Differences in D-dimer blood concentration in atrial fibrillation patients with left atrial thrombus or severe left

Changjian Lin1, Yangyang Bao1, Wei Hua1

  • 1Department of Cardiology, Shanghai Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, No. 197, Ruijin Er Road, Shanghai, 200025, China.

Insights

In atrial fibrillation (AF) patients, lower D-dimer levels in severe left atrial spontaneous echo contrast (SLASEC) indicate a lower risk of left atrial thrombus (LAT) compared to those with LAT. D-dimer may predict LAT thrombolysis.

Area of Science:

  • Cardiology
  • Hematology
  • Diagnostic Imaging

Background:

  • Severe left atrial spontaneous echo contrast (SLASEC) is a precursor to left atrial thrombus (LAT) and a risk factor for thromboembolic events.
  • The role of D-dimer in excluding LAT in atrial fibrillation (AF) patients is suggested, but differences between SLASEC and LAT D-dimer levels are unclear.

Purpose of the Study:

  • To investigate whether D-dimer blood concentrations differ between AF patients with SLASEC and those with LAT.
  • To evaluate D-dimer as a potential marker for distinguishing pre-thrombotic states from established thrombi.

Main Methods:

  • Prospective study of nonvalvular AF patients undergoing TEE for SLASEC or LAT detection.
  • D-dimer concentrations and CHA2DS2-VASc scores were measured and evaluated.
  • Follow-up for thromboembolic complications in the SLASEC group.

Main Results:

  • AF patients with SLASEC had significantly lower D-dimer levels (0.26±0.13 mg/L) and CHA2DS2-VASc scores (2.3±0.9) compared to those with LAT (D-dimer: 0.86±0.9 mg/L, P<0.05; CHA2DS2-VASc: 3.1±1.5, P=0.02).
  • A D-dimer cut-off of 0.285 mg/L showed 77.3% sensitivity and 80.0% specificity for predicting LAT.
  • D-dimer levels decreased significantly after anticoagulation treatment in patients with resolved LAT (0.42±0.22 vs. 0.33±0.18 mg/L, P=0.03).
  • No thromboembolic events occurred in the SLASEC group during follow-up.

Conclusions:

  • Lower D-dimer concentrations and CHA2DS2-VASc scores are associated with SLASEC compared to LAT in AF patients.
  • A D-dimer cut-off of 0.285 mg/L can help differentiate between pre-thrombotic states and LAT.
  • D-dimer may serve as a predictive marker for LAT resolution through anticoagulation.
Abstract

Related Concept Videos

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies01:20

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
89
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
89
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.2K
Imaging Studies for Cardiovascular System II:Types of Echocardiography01:20

Imaging Studies for Cardiovascular System II:Types of Echocardiography

Echocardiography plays a role in assessing cardiac health and detecting heart conditions, with various types providing critical insights for diagnosis and treatment.
Types of Echocardiography
Transthoracic Echocardiography (TTE)
TTE is the most common type of echocardiogram which involves placing a transducer on the patient's chest, emitting sound waves to create heart images. TTE is invaluable for evaluating the heart's size, structure, and motion, making it particularly useful for...
447
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies01:22

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
185
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.5K